Prime medicine reports full year 2023 financial results and provides business updates

-- maturing into clinical-stage company; on-track to file ind application or cta for pm359 in 1h 2024, with initial data expected in 2025 -- -- progressing broader portfolio across core areas of focus; expect to initiate ind-enabling activities in first liver and ocular disease programs in 2024 --
PRME Ratings Summary
PRME Quant Ranking